Aspirin for primary prevention of atherosclerotic cardiovascular events

Aldo L Schenone; A Michael Lincoff

doi:10.3949/ccjm.87a.19045

Aspirin for primary prevention of atherosclerotic cardiovascular events

Cleve Clin J Med. 2020 May;87(5):300-311. doi: 10.3949/ccjm.87a.19045.

Authors

Aldo L Schenone¹, A Michael Lincoff²

Affiliations

¹ Non-Invasive Cardiovascular Imaging Department, Brigham and Women's Hospital, Boston, MA.
² Department of Cardiovascular Medicine; Heart, Vascular, and Thoracic Institute; Director, C5Research (Cleveland Clinic Coordinating Center for Clinical Research); Director, Center for Clinical Research, Lerner Research Institute, Cleveland Clinic; Professor of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH lincofa@ccf.org.

PMID: 32357985
DOI: 10.3949/ccjm.87a.19045

Abstract

Recent trials evaluated the impact of aspirin for primary prevention of cardiovascular events in patients at intermediate risk, patients with diabetes, and the elderly, and the results have been incorporated into the most recent professional guidelines. For the most part, the role of aspirin in primary prevention remains limited, albeit not adequately tested in those at higher risk.

Publication types

Review

MeSH terms

Aspirin / pharmacology*
Atherosclerosis / drug therapy*
Cardiovascular Diseases / prevention & control*
Heart Disease Risk Factors
Humans
Platelet Aggregation Inhibitors / pharmacology
Primary Prevention / methods

Substances

Platelet Aggregation Inhibitors
Aspirin